|
That's good news. If they can put this into practice, it seems that a test of the (PI-PL)Cbeta1 gene (PI-PL stands for phosphoinositide-phospholipase) could predict if a patient is more or less likely to respond to Vidaza. Presumably, that information could sway decisions about when to use Vidaza.
|